Background: Our aim was to compare the rate of structural recurrence between patients who had lesser doses of radioactive iodine (RAI) and those who had traditional greater doses for remnant ablation after total thyroidectomy for papillary thyroid carcinoma (PTC).
Methods: A retrospective cohort study of patients who had undergone thyroidectomy and RAI for PTC was undertaken. We divided the cohort into those who had < or =3 GBq (75 mCi) RAI (group A) and those who had >3 GBq (75 mCi) RAI (group B). The primary outcome measure was the rate of structural recurrence.
Results: Of 1,171 patients with PTC from 1990 to 2012 who were followed for a mean of 60 months, 970 with T1–T3 tumors underwent RAI in addition to thyroidectomy. The mean first dose of RAI was 2.5 GBq (68 mCi) for group A (n = 153) and 4.7 GBq (127 mCi) for group B (n = 817; P < .001). The overall rate of recurrence was 8%. When corrected for T stage, the recurrence rates were not different for T1 tumors (2% group A versus 4% group B; P = .54) nor for T2 and T3 tumors (P = .36 and .55, respectively). On multivariate analysis, the dose of RAI was not an independent predictor for structural recurrence.
Conclusion: Decreasing the dose of RAI at initial ablation for patients with pT1–pT3 PTC does not seem to be associated with an increased risk of structural cancer recurrence.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.surg.2013.06.034 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Interplay Between High Cumulative Doses of Radioactive Iodine and Type 2 Diabetes Mellitus: A Complex Cardiovascular Challenge.
Int J Mol Sci
December 2024
Nuclear Medicine Department, University of Medicine and Pharmacy "Carol Davila" Bucharest, 050474 Bucharest, Romania.
Starting from the metabolic profile of type 2 diabetes mellitus (T2DM), we hypothesized that the mechanisms of ¹³¹I-induced cardiotoxicity differ between patients diagnosed with differentiated thyroid cancer (DTC) with/without T2DM, with metformin potentially acting as a cardioprotective agent by mitigating inflammation in patients with T2DM. To address this hypothesis, we quantified, using ELISA, the serum concentration of several key biomarkers that reflect cardiac injury (NT-proBNP, NT-proANP, ST2/IL-33R, and cTn I) in 74 female patients with DTC/-T2DM and 25 with DTC/+T2DM treated with metformin. All patients received a cumulative oral dose of I exceeding 150 mCi (5.
View Article and Find Full Text PDFAnimal-based radiation absorbed dose evaluation of holmium-166 labeled hydroxyapatite particulates in liver malignancies.
Asia Ocean J Nucl Med Biol
January 2025
Nuclear Fuel Cycle Research School, Nuclear Science and Technology Research Institute, Tehran, Iran.
Article Synopsis
- Liver cancer is a major cause of cancer deaths, and using beta-emitting radionuclides in targeted treatments like Ho-hydroxyapatite (Ho-HA) is a promising approach.
- The study estimated radiation absorbed doses of Ho-HA in the liver and other tissues using specific calculation methods, revealing that over 84% of the dose concentrated in liver tissue.
- Ho-HA treatment allows for high doses to the tumor while minimizing exposure to healthy tissues, suggesting its potential effectiveness for liver cancer therapy.
Radiation safety and dialysate analysis in hemodialysis following Lu-177-PSMA-617 therapy: A case report.
Radiol Case Rep
January 2025
Department of Hematology and Medical Oncology, Koo-Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan.
Purpose: We present a patient who is undergoing regular HD and received Lu-177-PSMA-617 treatment, regarding radiation safety issues including environmental radiation, exposure of medical personnel, and the radioactivity in the dialysate.
Methods: A 78 years old man with metastatic castration-resistant prostate cancer undergoing HD received 84.4 mCi (3.
Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial.
Lancet Diabetes Endocrinol
January 2025
Department of Biostatistics and Epidemiology, Gustave Roussy, Paris, France; University Paris-Saclay, Paris, France; Office of Biostatistics and Epidemiology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Inserm, Université Paris-Saclay, CESP U1018, Oncostat, labelled Ligue Contre le Cancer, Villejuif, France.
Background: ESTIMABL2, a multicentre randomised phase 3 trial in patients with low-risk differentiated thyroid cancer (ie, pT1am or pT1b, N0 [no evidence of regional nodal involvement] or Nx [involvement of regional lymph nodes that cannot be assessed in the absence of neck dissection]), showed the non-inferiority of a follow-up strategy without radioactive iodine (I) administration compared with a postoperative I administration at 3 years post-randomisation. Here, we report a pre-specified analysis after 5 years of follow-up.
Methods: Patients treated with total thyroidectomy with or without prophylactic neck lymph node dissection, without postoperative suspicious findings on neck ultrasonography, were randomly assigned to the no-radioiodine group or to the radioiodine group (1·1 GBq-30 mCi after recombinant human thyrotropin-stimulating hormone).
Nasolacrimal Duct Obstruction Following Radioactive Iodine: An Update on Counseling Recommendations for Thyroid Cancer Survivors.
Endocr Pract
November 2024
Department of Endocrinology, Gerontology, & Metabolism, Stanford Medical Center, Palo Alto, California.
Objective: Radioactive iodine (RAI) treatment for thyroid carcinoma may induce nasolacrimal duct obstruction. Evidence-based recommendations regarding nasolacrimal screening and prophylactic management in thyroid cancer survivors are lacking.
Methods: A case control study of patients treated with radioactive iodine for thyroid carcinoma was performed, comparing those who developed symptomatic nasolacrimal duct obstruction (group 1) to age- and gender-matched controls who did not develop nasolacrimal duct obstruction (group 2), to identify risk factors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!